Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Biogen Aducanumab BLA Plan Is In Line With US FDA Neurology Division Precedent

Nov 11 2019

• By Bridget Silverman

Blueprint-light-bulb

Related Content

Keeping Track Of Non-Oncology Review and Approval News: Erectile Dysfunction, Parkinson's, Cholesterol

Mar 03 2019

FDA's First Step In Xenazine Review: Work Around Clinical Evidence Guidance

Mar 01 2009

Revisiting <em>Xenazine</em>’s Extraordinary Review: A Study In FDA Flexibility

Feb 24 2014

BioMarin's Drisapersen 'Compete Response' Shows FDA Flexibility Still Limited

Jan 14 2016

Defining 'Substantial Efficacy': Post Hoc Analysis OK (When US FDA Does It)

Dec 07 2015

Rhone-Poulenc Rorer Rilutek (riluzole) for ALS approved Dec. 12, five-and-a-half months after NDA submission.

Dec 18 1995

FDA Reverses Position On Fabre-Kramer's Gepirone, Clearing Way For Approval

Mar 18 2016

An About Face As Biogen Says It Will File Aducanumab In Alzheimer’s

Oct 23 2019

Related Companies

Biogen, Inc.

Eisai Co., Ltd.

Kyowa Kirin Co., Ltd.

Sanofi

Covis Pharma B.V.

Bausch Health Companies Inc.

Bausch Health Companies Inc.

Mitsubishi Tanabe Pharma Corporation

Teva Pharmaceutical Industries Ltd.

Fabre-Kramer Pharmaceuticals

BioMarin Pharmaceutical Inc.

Additional Topics

United States Drug Approval Standards Drug Review Regulation Neurology BioPharmaceutical

More from Approval Standards

More from Pathways & Standards

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.